Day One - Pre-Day - Western European Summer Time (WEST)
Goodwin Insights: 2025 Deal Trends and the Importance of Being Opportunistic in Today’s Biotech Market
- Financing: The market is increasingly “winner takes all,” with capital becoming more concentrated and flowing into fewer financing rounds.
- M&A: Robust M&A activity in 2025 is expected to continue into 2026. We will share insights from Goodwin’s 2025 transactions, including the sales of ViceBio to Sanofi, Dark Blue Therapeutics to Amgen, and ImCheck to Ipsen.
- IPO Market: Momentum is building for a potential upswing in IPO activity in 2026. Does Agomab’s IPO signal renewed opportunity for other European companies?
- Strategic Opportunism: How biotech companies can position themselves to act quickly and effectively as attractive deal opportunities arise.
This closed-door forum operates under Chatham House rules, ensuring participants can share candidly without attribution. The discussion-based format encourages active participation for deeper exploration of specific challenges relevant to your business stage and therapeutic focus.
Breaking Barriers: Mastering FDA Regulations, National Security, and Tariffs to Expand Your MedTech Company to the US
Expanding a MedTech company from Europe to the US is a complex journey that requires more than just innovative technology. It demands a strategic approach to navigating regulatory landscapes, national security considerations, and tariff implications. In this session, we’ll explore how MedTech leaders can break through these barriers by leveraging the right expertise and partnerships to address these challenges effectively.
We’ll break down the critical components of successfully entering the US market, including understanding and complying with FDA regulations, addressing national security concerns, and managing tariff-related complexities. This session will provide actionable insights and strategies for MedTech leaders to ensure a smooth and compliant transition into the US market.
Key Discussion Points
- Why understanding FDA regulations and national security considerations is critical for MedTech companies entering the US market
- Developing strategic solutions to navigate regulatory, security, and trade challenges in the US market
- Complexities of raising money with US expansion in mind
- Practical approaches to building partnerships and leveraging resources to streamline market entry
Introduction: Who Buchanan Are and Key Industry Insights (13:30–13:50)
- A short introduction to our partners Buchanan, their expertise, and the most pressing issues they are observing in the MedTech space.
- This segment will set the stage for the discussion by highlighting the challenges and opportunities for European MedTech companies entering the US market.
Fireside Chat (13:50–14:30)
- An interactive discussion featuring operators and investors in the MedTech space.
- Panellists will share their experiences, insights, and strategies for overcoming regulatory, security, and trade challenges when expanding into the US.
- This session will provide real-world examples and actionable advice for attendees.
Open discussion (14:30–15:00)
- An opportunity to share advice, experiences and ask questions of the other medtech leaders in the room.
- Attendees will have the opportunity to ask questions directly to the panellists and discuss specific challenges or concerns they are facing.
- This segment is designed to foster meaningful dialogue and provide tailored insights.
To encourage open and honest discussions, the forum will operate under the Chatham House Rule. Participants are free to use the information shared, but neither the identity nor the affiliation of the speakers or participants may be revealed.
This session is for MedTech C-suite executives and senior decision-makers only.
Navigating the Path to Public Markets: Strategies for Success
The journey to becoming a publicly traded company is evolving, with traditional IPOs showing signs of improvement and alternative routes returning. This session will explore the current state of the market, standard and innovative approaches to going public, and strategies for securing late-stage funding to ensure a successful public raise. Join industry leaders and experts as they share insights, practical advice, and real-world examples to help you navigate this critical phase of growth.
Session Focus: Key Discussion Points
- Traditional IPOs and Market Outlook
- Overview of the current state of the IPO market and signs of improvement.
- Key factors driving renewed interest in traditional IPOs.
- Unique Routes to the Public Market
- Exploring alternative pathways such as reverse mergers, de-SPACs, sign & close deals, APOs and initial listings.
- Pros and cons of these approaches and how they compare to traditional IPOs.
- Strategic nuances for non-US companies based on home jurisdiction and listing status outside the US
- Securing Late-Stage Funding
- Strategies for securing late-stage funding to strengthen your position before a public raise.
- Insights into investor expectations and preparing for the transition to public markets.
- Bill Hicks - Partner, CO-Chair of Securities & Capital Markets Group, Mintz
- Ryan Dolan - Senior Managing Partner, Life Sciences Leader, CFGI